436results about How to "Low antigenicity" patented technology

This invention provides a fibrin sealant dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, antiinflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of preparing and/or using the unsupplemented or supplemented fibrin sealant dressing.

The present invention provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a (“PCSK9”) and methods of using such antibodies.

A method for promoting autogenous ingrowth of damaged or diseased tissue selected from a group consisting of ligaments, tendons, muscle and cartilage, the method comprising a step of surgically repairing the damaged or diseased tissue by attachment of a tissue graft, wherein the tissue graft is formed from a segment of connective tissue protein after an acellularization process, the segment being crosslinked with genipin, its analog or derivatives. The genipin-fixed acellular tissue provides a microenvironment for tissue regeneration adapted for use as a biological implant device due to its low cytotoxicity.

A terminally modified polymer is provided herein. At least one terminus of the polymer is —O—(CH₂)₂-L^M or —O—CH₂—CH(OH)—CH₂—CR¹═CR²R³. L^M, R¹, R², and R³ are defined herein Also disclosed are terminal conjugates comprising the polymer and a pharmaceutically useful modifier, as well as compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

The invention discloses a decellularized pericardial tissue via chemical treatment with cholic acid or bile salts as a medical device and process of manufacture.

A venous valve device and method of formation are described to provide antegrade blood flow in the deep venous vessels of the leg or in other venous vessels of the body having incompetent or irreversibly dysfunctional valves. The venous valve device is made of a sheet of biocompatible material, comprising a longitudinal wire-frame structure that is a continuous seamless wire loop and plural anchoring mesh-lattice wing members spaced apart and connected to the base of the wire-frame structure.

The invention provides fibronectin-based binding molecules and methods for introducing donor CDRs into a fibronectin-based binding scaffold, in particular, Fn3. The fibronectin-based binding molecules of the invention may be further conjugated to another moiety, for example, Fc, anti-FcRn, HSA, anti-HSA, and PEG, for improved half life and stability, particularly in mammalian cells. The invention also provides methods for screening such molecules for binding to a target antigen as well as the manufacture and purification of a candidate binder.

The invention relates to a guided tissue regeneration membrane, which comprises a compact coating and a loose coating, wherein the compact coating is composed of collagen-I or collagen-I composite hyaluronic acid; and the loose coating is composed of collagen-I or collagen-I composite calcium salt. A preparation method of the guided tissue regeneration membrane comprises the following steps of: preparing a collagen solution or a collagen and hyaluronic acid mixed solution by the use of acetic acid; injecting the solution into a self-made die, and drying it in the air to prepare the compact coating; injecting the collagen solution or a mixed liquor of the collagen solution and calcium salt onto the compact coating, and uniformly spreading; precooling the die at ultralow temperature, followed by freeze-drying to prepare the guided membrane with the compact coating and loose coating structure; carrying out vacuum high-temperature crosslinking and chemical crosslinking; and finally cleaning. The regeneration membrane has good histocompatibility and mechanical strength, low antigenicity and strong guided tissue regeneration capability. Its degradation rate in vivo is 3-8 months. The method is easy to operate, is suitable for automatic and continuous large-scale production, and solves the problems of large size of collagen membrane and material uniformity during industrial production.

The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.

A new root canal filling point which is physicochemically stable, is not toxic to periapical tissue, can be sterilized and x-rayed; and has high elasticity and fracture resistance which enables the root canal filling point to be pressure-inserted into an even narrow or curved root canal. The root canal filling point is made of a copolymer consisting of propylene and ethylene, and a contrast medium.

The present invention relates to bispecific molecules that are characterized by having a first binding domain which binds an antigen present in the circulation of a mammal and a second binding domain which binds the C3b-like receptor (known as complement receptor 1 (CR1) or CD35 in primates). The bispecific molecules do not consist of a first monoclonal antibody to CR1 that has been chemically cross-linked to a second monoclonal antibody. The invention also relates to methods of making the bispecific molecules and therapeutic uses thereof, as well as to kits containing the bispecific molecules. The invention further provides polyclonal populations of bispecific molecules, which comprise populations of bispecific molecules with different antigen recognition specificities. Such polyclonal populations of bispecific molecules can be used for targeting multiple epitopes of a pathogenic antigenic molecule and/or multiple variants of a pathogenic antigenic molecule.

This invention provides supplemented tissue sealants, methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one cytotoxin or cell proliferation inhibiting composition. The composition may be further supplemented with, for example, one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, cytokines, drugs, growth factors, interferons, hormones, lipids, deminearlized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like.

The present invention concerns the treatment of tumours. In particular the invention concerns the combination of agents which are adapted to increase B7-H3 and agents which are adapted to decrease or inhibit one or more HIFs. In a preferred embodiment, a vector adapted to express B7-H3 is administered along with antisense HIF.